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The lipid-lowering and pleiotropic effects of statins,
including their anti-inflammatory actions, have led to the
use of these drugs in the prevention of adverse
cardiovascular events. Two clinical studies, 'Reversal of
Atherosclerosis with Aggressive Lipid Lowering
(REVERSAL),' which used high-dose atorvastatin (80
mg/day), and 'A Study to Evaluate the Effect of
Rosuvastatin on Intravascular Ultrasound-Derived
Coronary Atheroma Burden (ASTEROID),' in which high-
dose rosuvastatin (40 mg/day) was administered,
demonstrated non-progression or regression of
atherosclerosis after treatment, as determined by serial
intravascular ultrasound (IVUS) [1,2]. Serial IVUS allows
the highly detailed evaluation of neointimal hyperplasia
after stent implantation and of changes in plaque volume
in de novo lesions. Although many IVUS studies have
examined the efficacy of drugs aimed at the treatment of
atherosclerosis, including statins, there are few reports in
which this modality was used to analyze the effects of
statins on either plaque regression or vascular remodeling
in non-stented reference segments. These arterial
segments are rarely disease-free, typically have a
significant plaque burden, and may also have undergone
remodeling changes [3]. The IVUS study by Hong et al. [4]
was one of the few to evaluate the effects of the usual dose
of simvastatin on plaque regression and vascular
remodeling in peri-stent reference segments following the
implantation of a bare-metal stent (BMS) and is thus of
particular clinical significance. A comparison between the
main outcome of that study and the outcomes of previous
studies would provide a better understanding of the
different effects of the various types of statins on the
reference segments, the levels of low-density lipoprotein
cholesterol (LDL-C), and related parameters.
Hong et al. [4], in their retrospective analysis, reported
that the usual dose of simvastatin did not inhibit plaque
progression and lumen reduction, nor did it affect
vascular remodeling in peri-stent reference segments in
patients who underwent BMS implantation. In their
comparison of simvastatin and non-statin treatment
groups, the authors found no significant differences in the
changes in mean plaque plus media (P&M), lumen size, or
external elastic membrane (EEM) area between post-
stenting and follow-up, at either the proximal or the distal
edges of the stent. These results were slightly different
from those of other studies. For example, in an earlier
study by Jensen et al. [5], the effect of lipid lowering by
simvastatin on coronary atherosclerotic plaques was
investigated with respect to changes in EEM, P&M, and
lumen volumes. In 40 male patients with hypercholesterol-
emia, ischemic heart disease, and a non-significant
coronary artery lesion, a significant reduction in P&M
volume of 6.3% (p = 0.002) was observed after 12 months
of simvastatin treatment, whereas the 1.8% reduction in
EEM volume was not significant; there were also no
concomitant changes in lumen volume. Accordingly, the
study's authors concluded that 12 months of simvastatin
therapy resulted in significant plaque regression.
Similarly, another study evaluated in-stent neointimal
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hyperplasia and the changes of plaques at non-stented
sites after simvastatin treatment [6]. Although in this
study, 12-month statin treatment did not prevent intimal
hyperplasia, persistent plaques (-4.0 ± 4.0 vs. +1.6 ± 3.8
mm3/mm, -14% ± 10% vs. +6% ± 12%, p < 0.05) and
intermediate plaques (-2.5 ± 3.0 vs. +1.0 ± 3.0 mm3/mm,
-10% ± 8% vs. +9% ± 9%, p < 0.05) at non-stented sites
decreased in the simvastatin-treated group, but increased
in the control group. The findings of these three studies
can be interpreted as follows. First, as the Hong et al. [4]
also suggested, most previous studies involving serial
IVUS examination after simvastatin therapy were not
aimed at the assessment of vascular changes within the
peri-stent reference segment. Second, to evaluate and
understand the factors contributing to plaque regression,
it is necessary to consider LDL-C levels, which are
regarded as one of the most important factors
determining the progress of an atherosclerotic plaque. In a
prior serial IVUS follow-up study, follow-up LDL-C levels
were the strongest predictor of changes in mean P&M
area (r = 0.469; p < 0.001; 95% confidence interval,
0.003 to 0.006) [7]. In the study by Hong et al. [4], the
mean follow-up level of LDL-C in the simvastatin-treated
group was 92 ± 30 mg/dL, which was higher than the
optimal level of < 70 mg/dL, defined in the ASTEROID
study as the cut-off value for plaque regression. Therefore,
the decrease in LDL-C achieved using 20 mg simvastatin
would not be enough to cause plaque regression; rather, in
reference segments, a higher dose of the drug or more
effective statins would be needed to improve the reduction
of LDL-C. 
The other important factor in plaque reduction is the
anti-inflammatory action of statins, as determined by
decreases in C-reactive protein (CRP) levels. Inflammat-
ion plays an important role in atherosclerotic plaque
progression, and the anti-inflammatory effects of statins
have been well established in several studies [1,2,8]. A
significant reduction in CRP in the simvastatin-treated
group compared with the control group was noted by
Hong et al. [4] Further investigation into how CRP
reduction is related to plaque regression will be helpful in
confirming this association. In addition, an intercorr-
elation analysis between plaque regression and LDL-C or
CRP levels is needed.
In addition to the systemic factors such as LDL-C and
inflammatory markers, the local factors, including flow
dynamics, shear stress, and type of implanted stent, have
been reported to influence the vascular responses of
reference segments. Kaneda et al. [9] suggested that in-
stent lumen patency influences the vascular responses of
adjacent reference segments after BMS implantation. The
authors found that the lumen area in the smaller in-stent
minimal lumen area (MLA) group (MLA < 3 mm2)
decreased significantly at the distal edge compared with
the larger in-stent MLA group (MLA > 3 mm2). An
evaluation of the degree of neointimal growth will provide
insight into the changes occurring in persistent reference
segments.
The rupture of a vulnerable plaque is the most
important mechanism leading to an acute coronary
syndrome. This potentially fatal event may be strongly
related to the specific components of the plaque.
Therefore, treatment options for stabilizing vulnerable
plaques and therapeutic strategies to reduce plaque
volume are drawing increasing attention. In an earlier
serial virtual histology study using an IVUS, plaques were
characterized as having a calcified, fibrotic, or necrotic
core, and each plaque was examined after the admin-
istration of one of two types of statin therapy [10]. In that
study, rosuvastatin treatment achieved a statistically
significant decrease in necrotic core volume (15.5 to 13.0
mm3, p = 0.015) and an increase in fibrofatty plaque
volume (4.5 to 5.9 mm3, p = 0.017), whereas the effects of
simvastatin were not significant. This result leads to the
conclusion that, besides an evaluation of plaque volume
changes using gray-scale IVUS, a second diagnostic tool is
needed to evaluate the changes in specific plaque
components. 
With the widespread use of percutaneous coronary
intervention in the treatment of coronary artery diseases,
IVUS evaluation of both the vascular changes following
stent implantation and the effects of specific drugs,
including statins, on stented and reference segments has
come to play an important role in the current drug-eluting
stent (DES) era. The effects of statins on reference
segments after DES implantation remain to be
investigated. (Korean J Intern Med 2010;25: 353-355)
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